Affiliations
AffiliationItem in Clipboard
Independent association of extent of resection with survival in patients with malignant brain astrocytomaMatthew J McGirt et al. J Neurosurg. 2009 Jan.
. 2009 Jan;110(1):156-62. doi: 10.3171/2008.4.17536. AffiliationItem in Clipboard
AbstractObject: With recent advances in the adjuvant treatment of malignant brain astrocytomas, it is increasingly debated whether extent of resection affects survival. In this study, the authors investigate this issue after primary and revision resection of these lesions.
Methods: The authors retrospectively reviewed the cases of 1215 patients who underwent surgery for malignant brain astrocytomas (World Health Organization [WHO] Grade III or IV) at a single institution from 1996 to 2006. Patients with deep-seated or unresectable lesions were excluded. Based on MR imaging results obtained < 48 hours after surgery, gross-total resection (GTR) was defined as no residual enhancement, near-total resection (NTR) as having thin rim enhancement of the resection cavity only, and subtotal resection (STR) as having residual nodular enhancement. The independent association of extent of resection and subsequent survival was assessed via a multivariate proportional hazards regression analysis.
Results: Magnetic resonance imaging studies were available for review in 949 cases. The mean age and mean Karnofsky Performance Scale (KPS) score at time of surgery were 51 +/- 16 years and 80 +/- 10, respectively. Surgery consisted of primary resection in 549 patients (58%) and revision resection for tumor recurrence in 400 patients (42%). The lesion was WHO Grade IV in 700 patients (74%) and Grade III in 249 (26%); there were 167 astrocytomas and 82 mixed oligoastrocytoma. Among patients who underwent resection, GTR, NTR, and STR were achieved in 330 (35%), 388 (41%), and 231 cases (24%), respectively. Adjusting for factors associated with survival (for example, age, KPS score, Gliadel and/or temozolomide use, and subsequent resection), GTR versus NTR (p < 0.05) and NTR versus STR (p < 0.05) were independently associated with improved survival after both primary and revision resection of glioblastoma multiforme (GBM). For primary GBM resection, the median survival after GTR, NTR, and STR was 13, 11, and 8 months, respectively. After revision resection, the median survival after GTR, NTR, and STR was 11, 9, and 5 months, respectively. Adjusting for factors associated with survival for WHO Grade III astrocytoma (age, KPS score, and revision resection), GTR versus STR (p < 0.05) was associated with improved survival. Gross-total resection versus NTR was not associated with an independent survival benefit in patients with WHO Grade III astrocytomas. The median survival after primary resection of WHO Grade III (mixed oligoastrocytomas excluded) for GTR, NTR, and STR was 58, 46, and 34 months, respectively.
Conclusions: In the authors' experience with both primary and secondary resection of malignant brain astrocytomas, increasing extent of resection was associated with improved survival independent of age, degree of disability, WHO grade, or subsequent treatment modalities used. The maximum extent of resection should be safely attempted while minimizing the risk of surgically induced neurological injury.
Similar articlesMcGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H, Quinoñes-Hinojosa A. McGirt MJ, et al. Neurosurgery. 2008 Oct;63(4):700-7; author reply 707-8. doi: 10.1227/01.NEU.0000325729.41085.73. Neurosurgery. 2008. PMID: 18981880
Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H. Attenello FJ, et al. Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18. Ann Surg Oncol. 2008. PMID: 18636295 Clinical Trial.
Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C. Babu R, et al. J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9. J Neurosurg. 2016. PMID: 26452121
Chen Z, Prasad SC, Di Lella F, Medina M, Piccirillo E, Taibah A, Russo A, Yin S, Sanna M. Chen Z, et al. J Neurosurg. 2014 Jun;120(6):1278-87. doi: 10.3171/2014.2.JNS131497. Epub 2014 Apr 11. J Neurosurg. 2014. PMID: 24724851 Review.
Ducray F, Honnorat J. Ducray F, et al. Presse Med. 2007 Sep;36(9 Pt 2):1249-54. doi: 10.1016/j.lpm.2007.02.002. Epub 2007 Mar 12. Presse Med. 2007. PMID: 17350791 Review. French.
Hosainey SAM, Hald JK, Meling TR. Hosainey SAM, et al. Neurosurg Rev. 2022 Feb;45(1):479-490. doi: 10.1007/s10143-021-01549-7. Epub 2021 Apr 27. Neurosurg Rev. 2022. PMID: 33905002 Free PMC article.
Xu R, Teich W, Frenzel F, Hoffmann K, Radke J, Rösler J, Faust K, Blank A, Brandenburg S, Misch M, Vajkoczy P, Onken JS, Resch-Genger U. Xu R, et al. Front Oncol. 2021 May 10;11:654300. doi: 10.3389/fonc.2021.654300. eCollection 2021. Front Oncol. 2021. PMID: 34041024 Free PMC article.
Giammalva GR, Brunasso L, Costanzo R, Paolini F, Umana GE, Scalia G, Gagliardo C, Gerardi RM, Basile L, Graziano F, Gulì C, Messina D, Pino MA, Feraco P, Tumbiolo S, Midiri M, Iacopino DG, Maugeri R. Giammalva GR, et al. Front Oncol. 2021 Mar 2;11:645854. doi: 10.3389/fonc.2021.645854. eCollection 2021. Front Oncol. 2021. PMID: 33738262 Free PMC article. Review.
Cho JM, Lim JJ, Kim SH, Cho KG. Cho JM, et al. Yonsei Med J. 2015 Mar;56(2):388-96. doi: 10.3349/ymj.2015.56.2.388. Yonsei Med J. 2015. PMID: 25683986 Free PMC article.
Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Ellingson BM, et al. Neuro Oncol. 2017 Jan;19(1):89-98. doi: 10.1093/neuonc/now187. Epub 2016 Aug 31. Neuro Oncol. 2017. PMID: 27580889 Free PMC article. Clinical Trial.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3